Synbiotic therapy (Bifidobacterium longum/Synergy 1) initiates resolution of inflammation in patients with active ulcerative colitis: a randomised controlled pilot trial

By E. Furrie, S. Macfarlane, Aileen Kennedy, J. Cummings, Shaun Walsh, O'neil Da, G. Macfarlane. Gut, 2005

759 citations recorded by the source corpus.

Subfields: Food Science, Infectious Diseases, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/17b5980e89193e8a5e032d310334e2690df208b7

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Food Science

1. T. Kanai
2. K. Matsuoka
3. K. Scott
4. P. Louis
5. M. Roberfroid

In Infectious Diseases

1. J. Costerton
2. N. Delzenne
3. T. Kanai
4. K. Matsuoka

In Molecular Biology

1. N. Delzenne
2. G. Gibson
3. J. Costerton
4. M. Shirtliff
5. T. Kanai
6. K. Matsuoka
7. K. Scott
8. Patrice D Cani

Citations in the corpus

• Dietary prebiotics: current status and new definition (2010, background): “A later study by Furrie et al. (2005) showed improved UC symptomology with a prebiotic (inulin) approach that increased gut bifidobacteria.”
• Inulin: Properties, health benefits and food applications. (2016, background): “Videla and Furrie concluded from a study in 18 active ulcerative colitis patients that, the use of prebiotics and probiotics in combination (i.e., B. longum and a prebiotic blend of inulin and oligofructose) cause reduction of intestinal inflammation (Furrie et al., 2005; Welters et al., 2002).”
• Bacterial metabolism and health‐related effects of galacto‐oligosaccharides and other prebiotics (2007, background): “Studies involving the use of prebiotics in human IBD are distinctly lacking; however, inulin and FOS have been shown to ameliorate inflammation in animal models of colitis, and in combination with probiotics in human trials (Cherbut et al. 2003; Schultz et al. 2004; Furrie et al. 2005).”
• Polymicrobial Interactions: Impact on Pathogenesis and Human Disease (2012, methodology): “acidophilus, Bifidobacterium bifidum, Bifidobacterium lactis, and Synergy 1 prebiotic and had been used in a previous study for the treatment of ulcerative colitis and Crohn’s disease (64, 199).”
• The gut microbiota and inflammatory bowel disease (2014, positive): “A pilot study demonstrated that Bifidobacterium longum/Synergy 1 improved intestinal inflammation in active UC patients [73].”
• Alteration of Gut Microbiota in Inflammatory Bowel Disease (IBD): Cause or Consequence? IBD Treatment Targeting the Gut Microbiome (2019, methodology): “longum, inulin, and oligofructose mixture used in a randomized double-blind controlled trial with UC patients demonstrated a reduction in endoscopic inflammation, and TNF-a and IL-1b levels [253].”